Related Articles
Hepatocellular carcinoma-targeted nanoparticles for cancer therapy
Non‑pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial
Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors